Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 193fludarabine phosphate 123Peripheral Blood Stem Cell Transplantation 107Etoposide 106Mycophenolic Acid 95Filgrastim 92Doxorubicin 85Whole-Body Irradiation 84Tacrolimus 81Brentuximab Vedotin 80Melphalan 78Busulfan 75Radiotherapy 74fludarabine 68Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 44pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × CF regimen × Lymphoid × Clear all
NCT04665063 2020-12-29

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
20 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡